Bricanyl 2.5 mg
1 tablet contains: Terbutaline sulphate 2.5 mg.
Company Name
CID/AstraZeneca
Pharmaceutical form
Tablet
Package
Box of 20 tablets .
Indications
Bronchial asthma, chronic bronchitis, emphysema and other lung diseases where bronchospasm is a complicating factor.
Warning & Precautions
- As for all B2-agonists caution should be observed in patients with thyrotoxicosis and in patients with severe cardiovascular disorder, such as ischemic heart disease, tachyarrhythmias or severe heart failure. - Due to the hyperglycemic effects of B2-agonists, additional blood glucose controls are recommended initially in diabetic patients. - Potentially serious hypokalemia may result from B2-agonist therapy. Particular caution is recommended in acute severe asthma as the associated risk may be augmented by hypoxia. The hypokalemic effect may be potentiated by concomitant treatments (see “Interactions”). It is recommended that serum potassium levels are monitored in such situations. - Use during pregnancy and lactation: * No teratogenic effects have been observed in patients or in animals. However, caution is recommended during the first trimester of pregnancy. * Terbutaline passes over to breast milk but an influence on the child is unlikely with therapeutic doses. * Transient hypoglycemia has been reported in newborn preterm infants after maternal B2-agonist treatment.
Product Type
human
Dosage
Bricanyl tablets should be used as maintenance therapy in asthma and other pulmonary diseases where bronchospasm is a complicating factor. Dosage should be individual. Adults: During the first 1-2 weeks: 2.5 mg 3 times in a 24 h period is recommended. The dose may then, if necessary, be increased to 5 mg 3 times in 24 hours. Children: 0.075 mg/kg body weight 3 times in 24 hours. Suitable dosage:
< 20 kg : ¼ - ½ tablets 3 times in 24 hours. 20- 30 kg : ½ - 1 tablets 3 times in 24 hours.
>30 kg: 1-2 tablets 3 times in 24 hours
Adverse Reactions
- The intensity of the adverse reactions depends on dosage and route of administration. An initial dose titration will often reduce the adverse reactions. Adverse reactions which have been recorded, e.g. tremor, headache, nausea, tonic muscle cramps, tachycardia and palpitations, are all characteristic of sympathomimetic amines. The majority of these effects have reversed spontaneously within the first 1-2 weeks of treatment. - As for all B2-agonists, cardiac arrhythmias, e.g. atrial fibrillation, supraventricular tachycardia and extrasystoles have been rarely reported. - Urticaria and exanthema may occur. - Sleep disturbances and behavioural disturbances, such as agitation, hyperactivity and restlessness, have been observed. - Bricanyl does not affect the ability to drive or use machines.
Contra Indications
Hypersensitivity to any of the ingredients.
Drug Interactions
- Beta-receptor blocking agents (including eye-drops), especially those which are non-selective, may partly or totally inhibit the effect of beta-receptor stimulants. - Hypokalemia may result from B2-agonist therapy and may be potentiated by concomitant treatment with xanthine derivatives, steroids and diuretics (see “Special warnings and precautions for use”).
No comments:
Post a Comment